6-Fluoro-2,2-dimethyl-1a,7b-dihydro-2H-1,3-dioxa-cyclopropa[a]naphthalene | 344883-15-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 6-Fluoro-2,2-dimethyl-1a,7b-dihydro-2H-1,3-dioxa-cyclopropa[a]naphthalene
• 英文别名: 6-Fluoro-2,2-dimethyl-1a,7b-dihydro-2h-oxireno[c]chromene；6-fluoro-2,2-dimethyl-1a,7b-dihydrooxireno[2,3-c]chromene
• CAS: 344883-15-4
• 化学式: C₁₁H₁₁FO₂
• 分子量: 194.206
• InChiKey: HOVYBIAWIZUPDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-methyl-ethanesulfonamide 、 6-Fluoro-2,2-dimethyl-1a,7b-dihydro-2H-1,3-dioxa-cyclopropa[a]naphthalene 在 sodium hydride 作用下， 以 二甲基亚砜 为溶剂， 反应 0.33h， 生成 Ethanesulfonic acid (6-fluoro-3-hydroxy-2,2-dimethyl-chroman-4-yl)-methyl-amide
  参考文献：
  名称：

  Synthesis and Activity of Novel and Selective I_Ks-Channel Blockers

  摘要：

  Since the discovery of the I-Ks-potassium channel as the slowly activating component of the delayed rectifier current (I-k) in cardiac tissue, the search for blockers of this current has been intense. During the screening of K-ATP-channel openers of the chromanol type we found that chromanol 293B was able to block I-Ks. Chromanol 293B is a sulfonamide analogue of the K-ATP-channel openers but had no activity on this target. Experiments were initiated to improve the activity and properties based on this lead compound. As a screening model we used Xenopus oocytes injected with human minK (KCNE1). Variations of the aromatic substituent and the sulfonamide group were prepared, and their activity was evaluated. We found that the greatest influence on activity was found in the aromatic substituents. The most active compounds were alkoxy substituted. We chose HMR1556 ((3R, 4S)-(+)-N-[-3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy)chroman-4-yl]-N-methyl-ethanesulfonamide) 10a for development as an antiarrhythmic drug. The absolute configuration, resulting from an X-ray single-crystal structure analysis, was determined.

  DOI：

  10.1021/jm0109255
• 作为产物：
  描述：

  2,2-dimethyl-6-fluorochromene 在 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 水 作用下， 以 乙醚 、 二甲基亚砜 为溶剂， 反应 0.5h， 生成 6-Fluoro-2,2-dimethyl-1a,7b-dihydro-2H-1,3-dioxa-cyclopropa[a]naphthalene
  参考文献：
  名称：

  取代的反式-4-氨基-3,4-二氢-2,2-二甲基-2H-1-苯并吡喃-3-醇的合成及降压活性。

  摘要：

  制备了一系列新型取代的反式-4-氨基-3,4-二氢-2,2-二甲基-2H-1-苯并吡喃-3-醇，并在有意识的乙酸脱氧皮质酮（DOCA）/盐水处理中测试了其降压活性。高血压大鼠。最佳的降血压活性需要一个强的吸电子基团与6位上的吡咯烷基或哌啶子基团一起进行6位取代。7-硝基-4-吡咯烷类似物和6-硝基-3-氯丙胺的例外，它们保留了明显的降压活性。所有这些化合物都是直接的血管扩张药，并且具有与肼屈嗪和钙拮抗剂硝苯地平相当的降压活性。这些化合物的合成路线包括将炔丙基醚环化为2H-1-苯并吡喃，然后通过溴代醇转化为3,4-环氧化物，用适当的胺开环。间取代的炔丙基醚在热环化反应中同时产生5-和7-取代的苯并吡喃，前者占优势。描述了一种新的制备2，2-二甲基-7-硝基苯并吡喃的途径。

  DOI：

  10.1021/jm00365a007

文献信息

• Multivariate Metal–Organic Frameworks as Multifunctional Heterogeneous Asymmetric Catalysts for Sequential Reactions
  作者：Qingchun Xia、Zijian Li、Chunxia Tan、Yan Liu、Wei Gong、Yong Cui

  DOI：10.1021/jacs.7b03113

  日期：2017.6.21

  The search for versatile heterogeneous catalysts with multiple active sites for broad asymmetric transformations has long been of great interest, but it remains a formidable synthetic challenge. Here we demonstrate that multivariate metal-organic frameworks (MTV-MOFs) can be used as an excellent platform to engineer heterogeneous catalysts featuring multiple and cooperative active sites. An isostructural

  长期以来，人们对寻找具有多个活性位点的多功能多相催化剂进行广泛的不对称转化一直很感兴趣，但它仍然是一个艰巨的合成挑战。在这里，我们证明了多元金属有机框架 (MTV-MOF) 可用作设计具有多个协同活性位点的多相催化剂的绝佳平台。构建了包含多达三种不同手性金属盐催化剂的 2 倍互穿 MTV-MOF 的同构系列，并将其用作各种不对称顺序烯烃环氧化/环氧化物开环反应的高效且可回收的多相催化剂。框架的相互渗透使金属盐单元彼此相邻，允许协同激活，这导致在单个部分的总和上提高效率和对映选择性。在 MTV-MOF 中操纵分子催化剂可以控制活性和选择性的事实将有助于设计用于对映选择性过程的新型多功能材料。
• GERICKE, ROLF;BAUMGARTH, MANFRED;LUES, INGEBORG;BERGMANN, ROLF;PEYER, JAC+
  作者：GERICKE, ROLF、BAUMGARTH, MANFRED、LUES, INGEBORG、BERGMANN, ROLF、PEYER, JAC+

  DOI：——

  日期：——
• EVANS, J. M.;FAKE, C. S.;HAMILTON, T. C.;POYSER, R. H.;WATTS, E. A., J. MED. CHEM., 1983, 26, N 11, 1582-1589
  作者：EVANS, J. M.、FAKE, C. S.、HAMILTON, T. C.、POYSER, R. H.、WATTS, E. A.

  DOI：——

  日期：——
• Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols
  作者：John M. Evans、Charles S. Fake、Thomas C. Hamilton、Robert H. Poyser、Eric A. Watts

  DOI：10.1021/jm00365a007

  日期：1983.11

  position. Exceptions to this were the 7-nitro-4-pyrrolidine analogue and the 6-nitro-3-chloropropylamine, which retained marked antihypertensive activity. All of these compounds were direct vasodilators and had comparable antihypertensive activity to hydralazine and to the calcium antagonist, nifedipine. The synthetic route to these compounds involves cyclization of of propargyl ethers to 2H-1-benzopyrans

  制备了一系列新型取代的反式-4-氨基-3,4-二氢-2,2-二甲基-2H-1-苯并吡喃-3-醇，并在有意识的乙酸脱氧皮质酮（DOCA）/盐水处理中测试了其降压活性。高血压大鼠。最佳的降血压活性需要一个强的吸电子基团与6位上的吡咯烷基或哌啶子基团一起进行6位取代。7-硝基-4-吡咯烷类似物和6-硝基-3-氯丙胺的例外，它们保留了明显的降压活性。所有这些化合物都是直接的血管扩张药，并且具有与肼屈嗪和钙拮抗剂硝苯地平相当的降压活性。这些化合物的合成路线包括将炔丙基醚环化为2H-1-苯并吡喃，然后通过溴代醇转化为3,4-环氧化物，用适当的胺开环。间取代的炔丙基醚在热环化反应中同时产生5-和7-取代的苯并吡喃，前者占优势。描述了一种新的制备2，2-二甲基-7-硝基苯并吡喃的途径。
• Synthesis and Activity of Novel and Selective I_Ks-Channel Blockers
  作者：Uwe Gerlach、Joachim Brendel、Hans-Jochen Lang、Erich F. Paulus、Klaus Weidmann、Andrea Brüggemann、Andreas E. Busch、Hartmut Suessbrich、Markus Bleich、Rainer Greger

  DOI：10.1021/jm0109255

  日期：2001.11.1

  Since the discovery of the I-Ks-potassium channel as the slowly activating component of the delayed rectifier current (I-k) in cardiac tissue, the search for blockers of this current has been intense. During the screening of K-ATP-channel openers of the chromanol type we found that chromanol 293B was able to block I-Ks. Chromanol 293B is a sulfonamide analogue of the K-ATP-channel openers but had no activity on this target. Experiments were initiated to improve the activity and properties based on this lead compound. As a screening model we used Xenopus oocytes injected with human minK (KCNE1). Variations of the aromatic substituent and the sulfonamide group were prepared, and their activity was evaluated. We found that the greatest influence on activity was found in the aromatic substituents. The most active compounds were alkoxy substituted. We chose HMR1556 ((3R, 4S)-(+)-N-[-3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy)chroman-4-yl]-N-methyl-ethanesulfonamide) 10a for development as an antiarrhythmic drug. The absolute configuration, resulting from an X-ray single-crystal structure analysis, was determined.